



Newsflow

Figure 5: Potential newsflow and catalysts

Timing	Event	Description
Mid-15	Competitor	Potential approval of LAMA/LABA tiotropium/voladaterol for COPD
Nov-15	Avodart	US patent expiry
2H15	Breo	Headline results from mortality/morbidity study (SUMMIT)
03-Nov-15	R&D	Investor day to update on pharmaceutical and vaccine pipelines
4Q15	Mepolizumab	US regulatory decision in severe asthma
2015	Mosquirix	EMA approval decision on malaria vaccine
2015	Sirukumab	Phase III data in rheumatoid arthritis (RA)
2015	Investigation	Possible outcome of SFO investigation
2H15	HZ/su	Data from trial of Herpes Zoster vaccine in the elderly
2H15	Competitor	Possible filing by Mylan for substitutable Advair generic
2H16	Breo	Results of SALFORD real world outcomes trial in COPD
2016	Shingrix	File for regulatory approval for shingles vaccine
2016	Competitor	First submission planned for Advair generic by Teva
2H16	Advair	Possible first US launch of Advair generics
2H16	Closed triple	Results of Phase III trials of closed triple combo in COPD
2016	Competitor	Expected launch of I.V. reslizumab for severe asthma
2018	Competitor	Expected launch of subcut reslizumab for severe asthma
Mid-15	Competitor	Potential approval of LAMA/LABA tiotropium/voladaterol for COPD
Nov-15	Avodart	US patent expiry
2H15	Breo	Headline results from mortality/morbidity study (SUMMIT)

Source: Deutsche Bank